GLPwatch
Papers (9189)
Page 18 of 154, ranked by citation count.
- Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving β-catenin.
- Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.
- Exendin-4 Enhances Motor Function Recovery via Promotion of Autophagy and Inhibition of Neuronal Apoptosis After Spinal Cord Injury in Rats.
- Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.
- Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study.
- Featured article: Structure moderation of gut microbiota in liraglutide-treated diabetic male rats.
- GLP-1 improves the neuronal supportive ability of astrocytes in Alzheimer's disease by regulating mitochondrial dysfunction via the cAMP/PKA pathway.
- Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy.
- Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.
- Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo.
- Liraglutide improves cognitive impairment via the AMPK and PI3K/Akt signaling pathways in type 2 diabetic rats.
- Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix.
- Synaptotagmin-7 phosphorylation mediates GLP-1-dependent potentiation of insulin secretion from β-cells.
- Cardioprotective effects of exenatide against oxidative stress-induced injury.
- Association of pancreatitis with glucagon-like peptide-1 agonist use.
- A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice.
- A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients.
- Intestinal glucagon-like peptide-1 effects on food intake: Physiological relevance and emerging mechanisms.
- Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.
- Glucagon-like peptide agonists: A prospective review.
- Cardiovascular effects of glucagonlike peptide-1 agonists.
- Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
- In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis.
- Liraglutide Compromises Pancreatic β Cell Function in a Humanized Mouse Model.
- The GLP-1 Receptor Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy.
- The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics.
- Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.
- Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4.
- Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial.
- Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial.
- Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.
- Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.
- Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice.
- Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program.
- SIRT1/HSF1/HSP pathway is essential for exenatide-alleviated, lipid-induced hepatic endoplasmic reticulum stress.
- β-Cell-specific protein kinase A activation enhances the efficiency of glucose control by increasing acute-phase insulin secretion.
- Central GLP-1 receptor activation modulates cocaine-evoked phasic dopamine signaling in the nucleus accumbens core.
- Liraglutide Protects Against Brain Amyloid-β<sub>1-42</sub> Accumulation in Female Mice with Early Alzheimer's Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation.
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
- Tirzepatide Once Weekly for the Treatment of Obesity. Reply.
- Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction.
- Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature.
- Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation.
- Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.
- Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review).
- Lixisenatide for type 2 diabetes mellitus.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.
- Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
- Quality by design thinking in the development of long-acting injectable PLGA/PLA-based microspheres for peptide and protein drug delivery.
- Liraglutide inhibits autophagy and apoptosis induced by high glucose through GLP-1R in renal tubular epithelial cells.
- Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
- Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension.
- Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide.
- Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial.
- Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor.
- Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.
- Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.
- Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5×FAD mouse model of Alzheimer's disease.
- Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis.
- Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity.